ABT-925

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Dopamine D3 receptors have been pharmacologically engaged in humans since the development of the first antipsychotics and ergot… (More)
  • table 1
  • table 1
  • figure 1
Is this relevant?
2013
2013
ABT-925, a selective dopamine D3 receptor (DRD3) antagonist, was tested in schizophrenia. A DRD3 gene polymorphism results in an… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2012
Review
2012
The potential of D3 receptor antagonism to treat positive, negative, and cognitive symptoms of schizophrenia is reviewed on the… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
There is substantial preclinical and clinical evidence to suggest a potential role for the dopamine D₃ receptor in the treatment… (More)
Is this relevant?
2010
2010
Dopamine D3 receptors are preferentially localized in the limbic system and midbrain, and thus may be involved in the… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2010
2010
  • 2010
Dopamine D3 receptors (D3Rs) may afford the ability to treat a wide variety of neuropsychiatric disorders (Graff-Guerrero et al… (More)
Is this relevant?